Overview

Observational Study of the Durability of Seroconversion Chronic HBV Patients Who Seroconverted in a Previous Gilead-Sponsored Study of ADV.

Status:
Completed
Trial end date:
2006-04-01
Target enrollment:
Participant gender:
Summary
To investigate the durability of HBeAg seroconversion in patients with chronic hepatitis B virus infection (HBV) who have seroconverted while participating in a previous Gilead-sponsored study of adefovir dipivoxil.
Details
Lead Sponsor:
Gilead Sciences
Treatments:
Adefovir dipivoxil